+

WO1997008205B1 - Antibodies having two or more specificities for the selective elimination of cells in vivo - Google Patents

Antibodies having two or more specificities for the selective elimination of cells in vivo

Info

Publication number
WO1997008205B1
WO1997008205B1 PCT/EP1996/003734 EP9603734W WO9708205B1 WO 1997008205 B1 WO1997008205 B1 WO 1997008205B1 EP 9603734 W EP9603734 W EP 9603734W WO 9708205 B1 WO9708205 B1 WO 9708205B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
tumor
antigens
cell
Prior art date
Application number
PCT/EP1996/003734
Other languages
German (de)
French (fr)
Other versions
WO1997008205A1 (en
Filing date
Publication date
Priority claimed from DE1995131348 external-priority patent/DE19531348A1/en
Application filed filed Critical
Publication of WO1997008205A1 publication Critical patent/WO1997008205A1/en
Publication of WO1997008205B1 publication Critical patent/WO1997008205B1/en

Links

Abstract

The invention concerns antibodies having two or more specificities detecting two different antigens localized on a tumour cell. The invention further concerns medicaments and diagnostic compositions containing these antibodies. The antibodies and medicaments described are suitable in particular for specifically detecting and eliminating tumour cells in vivo or in vitro.

Claims

GEÄNDERTE ANSPRÜCHE[beim Internationalen Büro am 14. April 1997 (14.04.97) eingegangen; ursprüngliche Ansprüche 1-20 durch geänderte Ansprüche 1-16 ersetzt (3 Seiten)] AMENDED CLAIMS [received at the International Bureau on 14 April 1997 (14.04.97); original claims 1-20 replaced by amended claims 1-16 (3 pages)]
1. Antikörper mit mindestens drei Spezifitäten, dadurch ge¬ kennzeichnet, daß von mindestens zwei Antigenbindungs- stellen des Antikörpers mit unterschiedlicher Spezifität zwei unterschiedliche auf einer Tumorzelle lokalisierte Antigene erkannt werden und eine weitere Antigenbin- dungsstelle mit einer weiteren Spezifität ein auf einer Effektorzelle lokalisiertes Antigen erkennt.1. Antibody having at least three specificities, characterized ge indicates that are recognized by at least two antigen binding sites of the antibody with different specificity two different located on a tumor cell antigens and another antigen binding site with a further specificity an isolated on an effector cell antigen recognizes.
2. Antikörper nach Anspruch 1, dadurch gekennzeichnet, daß von den Antigenbindungsstellen, die zwei unterschiedli¬ che auf der Tumorzelle lokalisierte Antigene erkennen, zwei verschiedene tumorassoziierte Antigene erkannt wer¬ den.2. Antibody according to claim 1, characterized in that two different tumor-associated antigens wer¬ recognized by the antigen binding sites that recognize two unterschiedli¬ che located on the tumor cell antigens.
3. Antikörper nach Anspruch 1, dadurch gekennzeichnet, daß von den Antigenbindungsstellen, die zwei unterschiedli¬ che auf der Tumorzelle lokalisierte Antigene erkennen, mindestens eine Antigenbindungsstelle ein tumorassozi¬ iertes Antigen erkennt und mindestens eine weitere Anti¬ genbindungsstelle ein Antigen erkennt, das auch von nicht-malignen Zellen exprimiert wird.3. Antibody according to claim 1, characterized in that of the antigen binding sites which recognize two unterschiedli¬ che on the tumor cell localized antigens, at least one antigen binding site recognizes a tumorassozi¬ iert antigen and at least one further anti¬ gene binding site recognizes an antigen that also from non-malignant cells is expressed.
4. Antikörper nach Anspruch 3, wobei das Antigen, das auch von nicht-malignen Zellen exprimiert wird, ein Antigen ist, das spezifisch für den Zeil- oder Gewebetyp des Tu¬ mors ist.4. The antibody of claim 3, wherein the antigen also expressed by non-malignant cells is an antigen specific to the cell or tissue type of the tumor.
5. Antikörper nach Anspruch 1, dadurch gekennzeichnet, daß von den Antigenbindungsstellen, die zwei unterschiedli¬ che auf einer Tumorzelle lokalisierte Antigene erkennen, zwei nicht-tumorspezifische Antigene erkannt werden, die in Kombination ausschließlich oder fast ausschließlich auf der Tumorzelle vorkommen. 5. An antibody according to claim 1, characterized in that two non-tumor-specific antigens are detected by the antigen binding sites that recognize two unterschiedli¬ che on a tumor cell located antigens that occur in combination exclusively or almost exclusively on the tumor cell.
6. Antikörper nach einem der Ansprüche 1 bis 5, wobei die auf der Tumorzelle lokalisierten Antigene die Antigene CD1, CD2, CD4, CD6, CD7, CD8, CD10, CDU, CD13 , CD14 , CD23, CD24, einen Ig-Idiotyp, CD30, CD33, CD37, CD40, CD41, c-erb-B2, CALLA (CD10) , MHCII, CD44v3 , CD44v6, CD71, p97, Gangliosid-GD_2, GD3 , C215, das von dem mono¬ clonalen Antikörper 17-IA-erkannte Antigen, das von dem monoclonalen Antikörper 9.2.27 erkannte Antigen, das von dem monoclonalen Antikörper NE150 erkannte Antigen, das von dem monoclonalen Antikörper L6 erkannte Antigen, das von dem monoclonalen Antikörper CA125 erkannte Antigen6. An antibody according to any one of claims 1 to 5, wherein the tumor cell located on the antigens antigens CD1, CD2, CD4, CD6, CD7, CD8, CD10, CDU, CD13, CD14, CD23, CD24, an Ig idiotype, CD30 , CD33, CD37, CD40, CD41, c-erb-B2, CALLA (CD10), MHCII, CD44v3, CD44v6, CD71, p97, ganglioside G D _ 2, GD3, C215, that of the monoethylenically clonal antibody 17- IA-recognized antigen, the antigen recognized by the monoclonal antibody 9.2.27, the antigen recognized by the monoclonal antibody NE150, the antigen recognized by the monoclonal antibody L6, the antigen recognized by the monoclonal antibody CA125
(Mucin) , das Antigen Lewis y, CD19, CD20, CD21, CD22, B220 oder CD5 sind.(Mucin), the antigen is Lewis y, CD19, CD20, CD21, CD22, B220 or CD5.
7. Antikörper nach einem der Ansprüche 1 bis 6, dadurch ge¬ kennzeichnet, daß das auf der Effektorzelle lokalisierte Antigen nicht auf der Tumorzelle vorhanden ist.7. Antibody according to one of claims 1 to 6, characterized ge indicates that the localized on the effector cell antigen is not present on the tumor cell.
8. Antikörper nach einem der Ansprüche 1 bis 7, dadurch ge¬ kennzeichnet, daß es sich bei dem auf der Effektorzelle lokalisierten Antigen um das Antigen CD3 , CD16, CD28, CD32 oder CD64 handelt.8. Antibody according to one of claims 1 to 7, characterized ge indicates that it is the antigen located on the effector cell to the antigen CD3, CD16, CD28, CD32 or CD64.
9. Antikörper nach einem der Ansprüche 1 bis 8, wobei es sich um einen monoclonalen Antikörper, einen durch re¬ kombinante DNA-Technologie hergestellten Antikörper, eine halbsynthetischen oder synthetischen Antikörper, um einen chemisch modifizierten Antikörper oder um ein Fragment eines solchen Antikörpers handelt.9. An antibody according to any one of claims 1 to 8, wherein it is a monoclonal antibody, an antibody produced by re¬ combinant DNA technology, a semisynthetic or synthetic antibody, a chemically modified antibody or a fragment of such an antibody.
10. Antikörper nach einem der Ansprüche 1 bis 9, wobei der Antikörper gekoppelt ist mit einem Enzym, einer toxi¬ schen Substanz, einem Radionuclid, Biotin oder einem Superantigen.10. An antibody according to any one of claims 1 to 9, wherein the antibody is coupled with an enzyme, a toxi¬'s substance, a radionuclide, biotin or a superantigen.
11. Arzneimittel enthaltend mindestens einen Antikörper nach einem der Ansprüche 1 bis 10. 11. A medicament containing at least one antibody according to any one of claims 1 to 10.
12. Verwendung eines Antikörpers nach einem der Ansprüche 1 bis 10 zur Herstellung eines Arzneimittels zur in vivo Immuntherapie .12. Use of an antibody according to any one of claims 1 to 10 for the manufacture of a medicament for in vivo immunotherapy.
13. Verwendung nach Anspruch 12, wobei die Immuntherapie eine Therapie zur Behandlung eines Tumors ist.13. Use according to claim 12, wherein the immunotherapy is a therapy for the treatment of a tumor.
14. Verwendung nach Anspruch 13, wobei der Tumor eine Leukämie, ein kolorektales Karzinom, ein Melanom, ein Ovarialkarzinom, ein Glioblastom (malignes Gliom) oder ein Mamma-Karzinom ist.14. Use according to claim 13, wherein the tumor is a leukemia, a colorectal carcinoma, a melanoma, an ovarian carcinoma, a glioblastoma (malignant glioma) or a mammary carcinoma.
15. Verwendung nach Anspruch 14, wobei die Leukämie ein B- Zell-Lymphom oder ein T-Zell-Lymphom ist.Use according to claim 14, wherein the leukemia is a B-cell lymphoma or a T-cell lymphoma.
16. Diagnostische Zusammensetzung enthaltend mindestens einen Antikörper nach einem der Ansprüche 1 bis 10. 16. A diagnostic composition comprising at least one antibody according to any one of claims 1 to 10.
PCT/EP1996/003734 1995-08-25 1996-08-23 Antibodies having two or more specificities for the selective elimination of cells in vivo WO1997008205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1995131348 DE19531348A1 (en) 1995-08-25 1995-08-25 Antibodies with two or more specificities for the selective elimination of cells in vivo
DE19531348.8 1995-08-25

Publications (2)

Publication Number Publication Date
WO1997008205A1 WO1997008205A1 (en) 1997-03-06
WO1997008205B1 true WO1997008205B1 (en) 1997-05-15

Family

ID=7770410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003734 WO1997008205A1 (en) 1995-08-25 1996-08-23 Antibodies having two or more specificities for the selective elimination of cells in vivo

Country Status (2)

Country Link
DE (1) DE19531348A1 (en)
WO (1) WO1997008205A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753368B1 (en) 1996-09-13 1999-01-08 Chauvin Jean Luc EXPANSIONAL OSTEOSYNTHESIS CAGE
BRPI9909860B8 (en) 1998-04-21 2021-05-25 Amgen Res Munich Gmbh multifunctional single-chain polypeptide, polynucleotide, vector, prokaryotic, yeast or unicellular cell, composition, uses of polypeptide and polynucleotide, and methods for preparing said polypeptide and for identifying activators or inhibitors of activation or stimulation of t cells
DE10034607A1 (en) 2000-07-20 2002-02-07 Gundram Jung Multi-specific reagent for the selective stimulation of cell surface receptors
DE10043437A1 (en) 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
AT413486B (en) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie USE OF AN ANTIBODY DIRECTED AGAINST LEWIS ANTIGENE
AT500648B1 (en) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie SET FOR THE TREATMENT OF CANCER PATIENTS
KR20060015602A (en) 2003-05-31 2006-02-17 마이크로메트 에이지 Pharmaceutical composition comprising a bispecific antibody against EVCA
CN100509850C (en) 2003-05-31 2009-07-08 麦克罗梅特股份公司 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP3151788A4 (en) 2014-06-04 2018-01-17 Wenzel Spine, Inc. Bilaterally expanding intervertebral body fusion device
JP7229176B2 (en) 2017-02-07 2023-02-27 オブリーク セラピューティクス アーベー Hydrocarbylsulfonyl-substituted pyridines and their use in treating cancer
US11219531B2 (en) 2019-04-10 2022-01-11 Wenzel Spine, Inc. Rotatable intervertebral spacing implant
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
DE4028955A1 (en) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh MONOCLONAL ANTIBODIES AGAINST THE INTERLEUKIN 2 RECEPTOR
FR2672291A1 (en) * 1991-01-31 1992-08-07 Inst Nat Sante Rech Med COMPOSITION OF ANTIBODIES DIRECTED AGAINST HUMAN OR ANIMAL INTERLEUKIN-2 RECEPTOR.
AU2400692A (en) * 1991-07-19 1993-02-23 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
WO1994024163A2 (en) * 1993-04-09 1994-10-27 Chiron Corporation Bispecific antigen-binding molecules

Similar Documents

Publication Publication Date Title
WO1997008205B1 (en) Antibodies having two or more specificities for the selective elimination of cells in vivo
Mezzanzanica et al. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components
US4978745A (en) Immunoreactive heterochain antibodies
Weiner et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII
AU761387B2 (en) Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore
MY108519A (en) Novel antibodies reactive with human carcinomas.
CA2067244C (en) Monoclonal antibody specific for iga receptor
Heuser et al. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells
EP0256654A3 (en) Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
EP0369566A2 (en) Bifunctional chimeric antibodies
WO1997007819B1 (en) Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated
Dorvillius et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen
Lloyd Human tumor antigens: detection and characterization with monoclonal antibodies
Thompson et al. Monoclonal antibodies to human colon and colorectal carcinoma
Carroll et al. Idiotype variant cell populations in patients with B cell lymphoma.
Michon et al. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody
EP0845998A1 (en) Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated
HUP9901597A2 (en) Method of killing target cells in harvested cell populations with one or more immuno-toxins
WO1997008205A1 (en) Antibodies having two or more specificities for the selective elimination of cells in vivo
Corvalan et al. Classification of anti-CEA monoclonal antibodies
Liao et al. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies
MASUCCI et al. Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948)
Holzer et al. Superantigen-staphylococal-enterotoxin-A-dependent and antibody-targeted lysis of GD 2-positive neuroblastoma cells
Bernhard et al. Induction of tumor‐cell lysis by bi‐specific antibody recognizing ganglioside GD2 and T‐cell antigen CD3
Bosslet et al. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载